. Author manuscript; available in PMC: 2019 Jun 1.

Published in final edited form as: Eur Urol Oncol. 2018 Jun 6;1(2):91–100. doi: 10.1016/j.euo.2018.03.005

Table 3.

Overview of comorbidity indices used to predict overall and bladder cancer–specific survival

Study	Sample size		Median FU	CI	Hazard ratio			ORC	AUC
Study	Total	RC	Median FU	CI	90-d mortality	OCM	CSM	ORC	AUC
Megwalu 2008 [47]	675	210	45 mo	ACE-27	NR	Overall: 1.39 RC: 1.36	NR	NR	Bootstrap: 0.636 (overall)
Mayr 2012 [19]	555	555	28 mo	ACE-27, CCI, ACCI, ECOG, ASA	NR	>75 yr or ASA 3–4 and ACE-27 >1: 3.34 >75 yr and ASA 3–4 and ACE-27 >1: 6.89	No significant predictors	NR	0.810
Boorjian 2013 [35]	891	891	10.1 yr	ASA, CCI, EI, ECOG	ASA: 3.17 ECOG: 2.4 EI: 1.48	ASA: 1.44 ECOG: 1.97	NR	NR	CCI: 0.798 EI: 0.770 ECOG: 0.769
Miller 2003 [45]	106	106	3.2 yr	CCI	NR	1.26	1.26	NR	NR
Froehner 2017 [46]	932	932	7.0 yr	ASA	NR	ASA 3–4: 1.74	NR	NR	NR

ACE-27 = Adult Comorbidity Evaluation 27 score; ACCI = age-adjusted CCI; ASA: American Society of Anesthesiology score; AUC = area under the receiver operating characteristic curve; CCI = Charlson CI; CI = comorbidity index; CSM = cancer-specific mortality; ECOG = Eastern Cooperative Oncology Group performance score; EI = Elixhauser Index; FU = follow-up; NR = not recorded; OCM = other-cause mortality; ORC = odds ratio for complications; RC = radical cystectomy.